These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20020482)

  • 1. A molecular mechanics model for imatinib and imatinib:kinase binding.
    Aleksandrov A; Simonson T
    J Comput Chem; 2010 May; 31(7):1550-60. PubMed ID: 20020482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tetracycline: Mg2+ complex: a molecular mechanics force field.
    Aleksandrov A; Simonson T
    J Comput Chem; 2006 Oct; 27(13):1517-33. PubMed ID: 16847933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanics models for tetracycline analogs.
    Aleksandrov A; Simonson T
    J Comput Chem; 2009 Jan; 30(2):243-55. PubMed ID: 18615434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty.
    Seeliger MA; Nagar B; Frank F; Cao X; Henderson MN; Kuriyan J
    Structure; 2007 Mar; 15(3):299-311. PubMed ID: 17355866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors.
    Lü S; Luo Q; Hao X; Li X; Ji L; Zheng W; Wang F
    Bioorg Med Chem Lett; 2011 Dec; 21(23):6964-8. PubMed ID: 22033461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl.
    Healy EF; Johnson S; Hauser CR; King PJ
    FEBS Lett; 2009 Sep; 583(17):2899-906. PubMed ID: 19660459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular interactions of c-ABL mutants in complex with imatinib/nilotinib: a computational study using linear interaction energy (LIE) calculations.
    Pereira EG; Moreira MA; Caffarena ER
    J Mol Model; 2012 Sep; 18(9):4333-41. PubMed ID: 22570081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl.
    Yang LJ; Zou J; Xie HZ; Li LL; Wei YQ; Yang SY
    PLoS One; 2009 Dec; 4(12):e8470. PubMed ID: 20041122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of binding energy activity of imatinib and Abl tyrosine kinase domain based on simple consideration for conformational change: An explanation for variation in imatinib effect in mutated type.
    Wiwanitkit V
    Indian J Cancer; 2009; 46(4):335-6. PubMed ID: 19749465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
    Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
    Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ONIOM DFT/PM3 calculation on the interaction between STI-571 and abelson tyrosine kinase.
    Xiong YZ; Chen PY
    J Mol Model; 2008 Nov; 14(11):1083-6. PubMed ID: 18663490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
    Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
    ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformational flexibility, binding energy, role of salt bridge and alanine-mutagenesis for c-Abl kinase complex.
    Dubey KD; Ojha RP
    J Mol Model; 2012 May; 18(5):1679-89. PubMed ID: 21811775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Explaining why Gleevec is a specific and potent inhibitor of Abl kinase.
    Lin YL; Meng Y; Jiang W; Roux B
    Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1664-9. PubMed ID: 23319661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
    Namboodiri HV; Bukhtiyarova M; Ramcharan J; Karpusas M; Lee Y; Springman EB
    Biochemistry; 2010 May; 49(17):3611-8. PubMed ID: 20337484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer research. Why some leukemia cells resist STI-571.
    Marx J
    Science; 2001 Jun; 292(5525):2231-3. PubMed ID: 11423629
    [No Abstract]   [Full Text] [Related]  

  • 17. Combining ab initio quantum mechanics with a dipole-field model to describe acid dissociation reactions in water: first-principles free energy and entropy calculations.
    Maurer P; Iftimie R
    J Chem Phys; 2010 Feb; 132(7):074112. PubMed ID: 20170220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation.
    Cowan-Jacob SW; Fendrich G; Manley PW; Jahnke W; Fabbro D; Liebetanz J; Meyer T
    Structure; 2005 Jun; 13(6):861-71. PubMed ID: 15939018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acid-base profiling of imatinib (gleevec) and its fragments.
    Szakács Z; Béni S; Varga Z; Orfi L; Kéri G; Noszál B
    J Med Chem; 2005 Jan; 48(1):249-55. PubMed ID: 15634018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D QSAR models built on structure-based alignments of Abl tyrosine kinase inhibitors.
    Falchi F; Manetti F; Carraro F; Naldini A; Maga G; Crespan E; Schenone S; Bruno O; Brullo C; Botta M
    ChemMedChem; 2009 Jun; 4(6):976-87. PubMed ID: 19326384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.